MULTIDISCIPLINARY TUMOUR BOARD: HOW DO WE APPROACH OLIGOPROGRESSIVE DISEASE?
Crizotinib-controlled ALK positive disease and three brain metastases
M. Guckenberger
Crizotinib-controlled ALK positive disease and three brain metastases
M. Guckenberger